IGC Pharma (IGC) vs TransCode Therapeutics (RNAZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
IGC Pharma (IGC) has outperformed TransCode Therapeutics (RNAZ) over the past year, losing 47.5% versus a loss of 86.6%. Over five years, IGC leads with a -87.6% price change compared with -100.0% for RNAZ. TransCode Therapeutics is the larger company by market cap ($20.1 million vs $19.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IGC | RNAZ |
|---|---|---|
| Share price | $0.168 | $1.16 |
| Market cap | $19.60M | $20.07M |
| 1-day change | -8.70% | -10.77% |
| YTD return | -40.00% | -83.02% |
| 1-year return | -47.50% | -86.57% |
| 5-year return | -87.65% | -100.00% |
| EPS (TTM) | $-0.07 | $-47.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.27M | — |
| Revenue growth (YoY) | -5.50% | — |
| Net income (latest FY) | $-7.12M | $-34.66M |
| Gross margin | 48.70% | — |
| Operating margin | -585.84% | — |
| Net margin | -560.35% | — |
| 52-week high | $0.36 | $12.60 |
| 52-week low | $0.08 | $1.01 |
| Distance from 52-week high | -53.33% | -90.79% |
| Analyst consensus | none | — |
| Avg. price target upside | +3471.43% | — |
| Average volume | 615.25K | 52.03K |
| Shares outstanding | 116.69M | 17.30M |
| Employees | 70 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IGC has outperformed RNAZ by 39.1 percentage points over the past year.
About IGC Pharma
IGC stock →IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's.
Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees
About TransCode Therapeutics
RNAZ stock →TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
IGC vs RNAZ FAQ
Which is bigger, IGC Pharma or TransCode Therapeutics?
TransCode Therapeutics (RNAZ) is larger, with a market capitalization of $20.07M compared with $19.60M for IGC Pharma (IGC).
Which stock has performed better over the past year, IGC or RNAZ?
IGC returned -47.50% over the past 12 months, compared with -86.57% for RNAZ (price return, excluding dividends). Past performance does not predict future results.
Are IGC Pharma and TransCode Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.